Owl Therapeutics – 1st FDA-Approved Drug for TBI - UNLOCKING WISDOM for BRAIN HEALTH Owl Therapeutics (“Owl”) is a clinical-stage biopharmaceutical company ready for investment in Phase 2 trials of derisked lead asset OWL-1410 to capture the $21B moderate and severe traumatic brain injury (TBI) market. Owl was created to develop best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for TBI and brain health. The company has rapidly built a promising, diversified pipeline of small and large molecule medicines poised to address the highly unmet needs of patients with neurodegenerative disease. Owl is led by a proven, cohesive, interdisciplinary, and internationally recognized team with deep scientific, clinical, and business experience in drug development and commercialization.